admin – Page 5328 – Get News Story

Fanconi Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, Foresee Pharma, Rocket Pharma, Jasper Therapeutics

The Key Fanconi Anemia Companies in the market include – Rocket Pharma, Foresee Pharmaceuticals, Jasper Therapeutics, Novartis, and others.

DelveInsight’s “Fanconi Anemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Fanconi Anemia, historical and forecasted epidemiology as well as the Fanconi Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Fanconi Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fanconi Anemia Market Forecast

Some of the key facts of the Fanconi Anemia Market Report:

The Fanconi Anemia market size was valued ~USD 51 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2023, the total number of diagnosed prevalent cases of Fanconi Anemia in the EU4 countries and the UK was around 3,000. Throughout the study period, a notable increase in cases is anticipated across all included countries. Among the EU4 nations, Germany had the highest share of Fanconi Anemia cases, while Spain reported the lowest.
Estimates indicate that the total diagnosed prevalent cases of Fanconi Anemia in Japan were approximately 1,100 in 2023, with this number projected to rise by 2034.
According to DelveInsight’s analysis, experts classified the mutation-specific cases of Fanconi Anemia by various mutations, such as FANCA, FANCC+FANCG, FANCE+FANCF, and others. In 2023, the FANCA category represented the largest number of cases in the United States, with approximately 2,000 cases.
DelveInsight’s findings indicate that around 43% of Fanconi Anemia cases in the 7MM were reported in the United States. In 2023, the EU4 and the UK together accounted for approximately 3,000 cases of Fanconi Anemia.
Key Fanconi Anemia Companies: Rocket Pharma, Foresee Pharmaceuticals, Jasper Therapeutics, Novartis, and others
Key Fanconi Anemia Therapies: RP-L102, FP-045, PS191, Deferasirox, and others
The Fanconi Anemia epidemiology based on gender analyzed that Fanconi anemia occurs slightly more in men as compare to women
The Fanconi Anemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fanconi Anemia pipeline products will significantly revolutionize the Fanconi Anemia market dynamics.

Fanconi Anemia Overview

Fanconi Anemia (FA) is a rare genetic disorder characterized by a failure of the bone marrow to produce enough blood cells, leading to various health issues, including aplastic anemia, increased susceptibility to infections, and a higher risk of cancers, particularly leukemia. The condition results from mutations in genes responsible for DNA repair, causing genomic instability. Patients often experience physical abnormalities, including skeletal issues and organ malformations. Diagnosis typically involves blood tests, genetic testing, and bone marrow evaluations. Treatment may include blood transfusions, bone marrow transplantation, and supportive care to manage symptoms and complications.

Get a Free sample for the Fanconi Anemia Market Report:

https://www.delveinsight.com/report-store/fanconi-anemia-market

Fanconi Anemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Fanconi Anemia Epidemiology Segmentation:

The Fanconi Anemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Fanconi Anemia
Prevalent Cases of Fanconi Anemia by severity
Gender-specific Prevalence of Fanconi Anemia
Diagnosed Cases of Episodic and Chronic Fanconi Anemia

Download the report to understand which factors are driving Fanconi Anemia epidemiology trends @ Fanconi Anemia Epidemiology Forecast

Fanconi Anemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fanconi Anemia market or expected to get launched during the study period. The analysis covers Fanconi Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fanconi Anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fanconi Anemia Therapies and Key Companies

RP-L102: Rocket Pharma
FP-045: Foresee Pharmaceuticals
PS191: Jasper Therapeutics
Deferasirox: Novartis

Discover more about therapies set to grab major Fanconi Anemia market share @ Fanconi Anemia Treatment Market

Fanconi Anemia Market Strengths

Fanconi anemia is a rare disease; thus, companies developing treatment options for the same can possess several advantages like market exclusivities, premium pricing, subsidy for conducting trials, and several other benefits from the government bodies for R&D.

Fanconi Anemia Market Opportunities

There is a huge opportunity for companies coming up with therapies as there will be fewer competition in the market. If the drugs are launched they will be in huge demand keeping in mind the unmet needs for this indication.

Scope of the Fanconi Anemia Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Fanconi Anemia Companies: Rocket Pharma, Foresee Pharmaceuticals, Jasper Therapeutics, Novartis, and others
Key Fanconi Anemia Therapies: RP-L102, FP-045, PS191, Deferasirox, and others
Fanconi Anemia Therapeutic Assessment: Fanconi Anemia current marketed and Fanconi Anemia emerging therapies
Fanconi Anemia Market Dynamics: Fanconi Anemia market drivers and Fanconi Anemia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Fanconi Anemia Unmet Needs, KOL’s views, Analyst’s views, Fanconi Anemia Market Access and Reimbursement

To know more about Fanconi Anemia companies working in the treatment market, visit @ Fanconi Anemia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Fanconi Anemia Market Report Introduction

2. Executive Summary for Fanconi Anemia

3. SWOT analysis of Fanconi Anemia

4. Fanconi Anemia Patient Share (%) Overview at a Glance

5. Fanconi Anemia Market Overview at a Glance

6. Fanconi Anemia Disease Background and Overview

7. Fanconi Anemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Fanconi Anemia

9. Fanconi Anemia Current Treatment and Medical Practices

10. Fanconi Anemia Unmet Needs

11. Fanconi Anemia Emerging Therapies

12. Fanconi Anemia Market Outlook

13. Country-Wise Fanconi Anemia Market Analysis (2020–2034)

14. Fanconi Anemia Market Access and Reimbursement of Therapies

15. Fanconi Anemia Market Drivers

16. Fanconi Anemia Market Barriers

17. Fanconi Anemia Appendix

18. Fanconi Anemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fanconi Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, Foresee Pharma, Rocket Pharma, Jasper Therapeutics

Scrubs and Nursing Uniforms Supplier Bayshore Medical Supply Celebrates Over 20 Years of Success as a Trusted Medical Supplier in Pasadena, TX

Bayshore Medical Supply is a family-owned business with more than two decades of experience in successfully fulfilling the medical needs of Pasadena and the surrounding areas. The medical community and patients trust its range of quality medical products and equipment.

According to announcements released by Bayshore Medical Supply and David Quyack, this scrubs and nursing uniforms supplier is celebrating over two decades of success in the business.

This family-owned business is a reliable provider of medical products and medical equipment for nursing homes and hospitals in Pasadena, Galena Park, Channelview, Baytown, League City, Deer Park, Pearland, and Greater South Houston.

Bayshore Medical Supply is a trusted provider of durable medical equipment, offering an extensive range of products tailored to meet the diverse needs of patients and healthcare professionals. With a dedicated and experienced staff’s knowledge ensures customers receive the right solutions for their medical needs. Each interaction provides the necessary information and support to help individuals feel confident in their choices.

A key strength of Bayshore Medical Supply is its large inventory of high-quality medical products. The selection includes reputable brands and various essential items such as KneeRover Knee Walkers and Knee Scooters, scooters, lift chairs, power chairs, and wheelchairs. For those seeking mobility aids, Bayshore Medical Supply offers a comprehensive selection designed to enhance independence and comfort. In addition to purchasing, customers can rent medical equipment, including knee walkers, wheelchairs, and transport chairs, offering flexible solutions for temporary or long-term needs.

Bayshore Medical Supply recognizes the importance of choice and comfort regarding nursing uniforms and scrubs. The store stocks various nursing uniforms in various sizes, ranging from XXS to 5X, with options for petite and tall individuals. Healthcare professionals working in the Pasadena and Southeast Houston areas, including facilities like Pasadena Health Center, VCare Community Medical & Dental Clinics, RediClinic Pasadena, Strawberry Health Center, CHI St. Luke’s Health Emergency Center–Pasadena, and HCA Houston Healthcare Southeast, will find uniforms that allow them to express their individuality.

For more information, visit https://bayshoremedicalsupply.net/

Unlike standard-issue hospital scrubs, Bayshore Medical Supply provides a variety of styles, colors, and patterns, enabling nurses to choose uniforms that reflect their personalities and preferences. The selection of nursing uniforms and scrubs at Bayshore Medical Supply is carefully curated to meet the specific needs of healthcare workers. With a commitment to superior quality, the store carries brands such as Cherokee and Dickies, known for their durability and trusted by nursing professionals.

These uniforms are made with breathable fabrics and designed to provide maximum comfort and ease of movement, ensuring that healthcare workers can perform their duties without any restrictions. The store’s focus on functionality and comfort makes it a go-to destination for professionals who require reliable and long-lasting uniforms.

Bayshore Medical Supply offers embroidery and other personalization services for those seeking even more customization. This allows healthcare professionals to add their names, departments, or organization logos to their uniforms, making them uniquely their own. Personalization not only adds a touch of individuality but also serves as a professional statement, reinforcing the connection between healthcare workers and the institutions they represent.

Bayshore Medical Supply’s commitment to meeting the needs of healthcare professionals extends to providing unisex options, ensuring that individuals of all genders can find comfortable and functional medical apparel. The company understands that the demands of the healthcare field require uniforms that are not only practical but also comfortable enough to wear throughout long shifts. With this in mind, Bayshore Medical Supply offers a wide selection of unisex scrubs designed to accommodate all body types and preferences.

Beyond medical apparel, Bayshore Medical Supply takes pride in its ability to service the equipment it sells. With decades of experience in the medical supply industry, the team is well-versed in maintaining and repairing a range of products, ensuring that customers’ equipment remains in top condition. Whether it’s a power chair, a scooter, or a lift chair, Bayshore Medical Supply provides in-house servicing, helping customers extend the life of their medical equipment and maintain their mobility and independence.

About the Company:

For more than 20 years, Bayshore Medical Supply has been the leading provider of medical supply products in Pasadena and Southeast Houston. It services everything it sells and also offers equipment on rent. The business’s staff is always on hand to help customers choose the best products.

Media Contact
Company Name: Bayshore Medical Supply
Contact Person: David Quyack
Email: Send Email
Phone: 713-472-8585
Address:4205 Spencer Hwy
City: Pasadena
State: TX 77504
Country: United States
Website: https://bayshoremedicalsupply.net/

Free Until You Rank SEO Program Launched By Green Hat Local SEO

Green Hat Local SEO, a trailblazer in the local search engine optimization industry, is thrilled to announce the launch of their revolutionary “Free Until You Rank SEO” program. This unparalleled approach to SEO is poised to disrupt the industry by providing customers with a risk-free solution to enhance their online presence and drive more traffic to their businesses.

The “Free Until You Rank SEO” program is engineered to assist local businesses in ranking their Google Business Profile (GBP) within the map pack in their service radius, without requiring any upfront investment. Green Hat Local SEO is so self-assured in their capacity to generate results that they are prepared to allocate their own resources until the customer’s GBP attains the desired ranking.

Dimitry Morgan, co-founder of Green Hat Local SEO, conveyed his zeal for the new program, declaring, “We recognize that numerous local businesses are apprehensive about investing in SEO due to the unpredictability of the outcome. With our ‘Free Until You Rank’ program, we are eradicating that uncertainty and exhibiting our dedication to our clients’ success. We are convinced that this program will revolutionize the manner in which local businesses approach SEO and aid them in realizing their online marketing objectives.”

The “Free Until You Rank” program is made possible by the extensive experience and expertise of Green Hat Local SEO’s founders, Dimitry Morgan and Kyle Sabraw. With a combined 30 years of SEO experience, they have developed a proven strategy for ranking GBPs in the map pack, which is a critical component of local search results.

Kyle Sabraw, co-founder of Green Hat Local SEO, added, “Our team has spent years perfecting our local SEO strategies, and we are confident that we can deliver results for our clients. By offering our services for free until the GBP ranks, we are showing our customers that we are fully invested in their success and are willing to put our money where our mouth is.”

The advantages of ranking in the map pack are substantial for local businesses. It can result in increased visibility, higher click-through rates, and ultimately, more customers. By collaborating with Green Hat Local SEO and capitalizing on the “Free Until You Rank” program, businesses can attain these benefits without any financial risk.

Green Hat Local SEO’s “Free Until You Rank” program encompasses a comprehensive range of services designed to optimize a business’s GBP and improve its local search rankings. These services include keyword research, citation building, on-page optimization, and content creation, among others.

To be eligible for the “Free Until You Rank” program, businesses must meet certain criteria, such as having a verified GBP and operating within a specific service radius. Interested businesses can visit the Green Hat Local SEO website to learn more about the program and to request a free consultation.

The launch of the “Free Until You Rank” program comes at a time when local businesses are increasingly recognizing the importance of online visibility and the impact it can have on their bottom line. With the COVID-19 pandemic accelerating the shift towards online commerce, having a strong presence in local search results has become more critical than ever.

Green Hat Local SEO’s innovative approach to SEO is a testament to their commitment to helping local businesses succeed in the digital age. By removing the financial barriers to entry and offering a risk-free solution, they are making it possible for more businesses to benefit from the power of local SEO.

Dimitry Morgan concluded, “We are excited to launch the ‘Free Until You Rank’ program and to partner with local businesses to help them achieve their online marketing goals. We believe that this program has the potential to transform the local SEO industry and to make a real difference in the lives of business owners across the country.”

About Green Hat Local SEO:

Green Hat Local SEO is a leading provider of local search engine optimization services, founded by Dimitry Morgan and Kyle Sabraw. With over 30 years of combined SEO experience, the company is dedicated to helping local businesses improve their online visibility and attract more customers through innovative and effective SEO strategies.

For more information visit https://ghls.io/

Media Contact
Company Name: Green Hat Local SEO
Contact Person: Kyle Sabraw
Email: Send Email
Phone: (619) 330-0953
Address:1135 Garnet Ave Suite 13
City: San Diego
State: CA
Country: United States
Website: https://ghls.io/

Gastroesophageal Adenocarcinoma Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Merck, Taiho Pharma, Sichuan Kelun-Biotech, ALX Oncology, AskGene Pharma, Inc., Akeso

The Key Gastroesophageal Adenocarcinoma Companies in the market include – Merck, Taiho Pharmaceuticals, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Trials Group, AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., CSPC ZhongQi Pharmaceutical, Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., LianBio LLC, Hoffmann-La Roche, Amgen, Phanes Therapeutics, and others.

DelveInsight’s “Gastroesophageal Adenocarcinoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastroesophageal Adenocarcinoma, historical and forecasted epidemiology as well as the Gastroesophageal Adenocarcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastroesophageal Adenocarcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroesophageal Adenocarcinoma Market Forecast

Some of the key facts of the Gastroesophageal Adenocarcinoma Market Report:

The Gastroesophageal Adenocarcinoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In June 2024, Arcus Biosciences has completed patient enrollment for the Phase III STAR-221 clinical trial, which evaluates the combination of domvanalimab and zimberelimab with chemotherapy in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (upper GI cancers). Domvanalimab is an Fc-silent anti-TIGIT antibody, while zimberelimab is an anti-PD-1 monoclonal antibody. Both therapies are currently under investigation.
In 2023, the total number of incident cases of gastroesophageal adenocarcinoma exceeded 220,000 across the 7MM.
In 2023, Japan recorded the highest number of incident cases of gastroesophageal adenocarcinoma among the 7MM.
In the US, Stage IV had the highest number of incident cases of gastroesophageal adenocarcinoma, whereas Japan reported the most cases in Stage I.
Key Gastroesophageal Adenocarcinoma Companies: Merck, Taiho Pharmaceuticals, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Trials Group, AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., CSPC ZhongQi Pharmaceutical, Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., LianBio LLC, Hoffmann-La Roche, Amgen, Phanes Therapeutics, and others.
Key Gastroesophageal Adenocarcinoma Therapies: KEYTRUDA (pembrolizumab), LONSURF (trifluridine/ tipiracil), Sacituzumab Tirumotecan (MK-2870), Evorpacept (ALX148), Paclitaxel, Trifluridine-Tipiracil, ASKB589, AK104, OBP-301, tucatinib, Docetaxel for injection (Albumin-bound), Zanidatamab, Trastuzumab deruxtecan, Capecitabine, Infigratinib, Atezolizumab, Bemarituzumab, PT886, and others
The Gastroesophageal Adenocarcinoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroesophageal Adenocarcinoma pipeline products will significantly revolutionize the Gastroesophageal Adenocarcinoma market dynamics.

Gastroesophageal Adenocarcinoma Overview

Gastroesophageal adenocarcinoma is a type of cancer that arises from the glandular cells lining the esophagus and the stomach. It is characterized by the abnormal growth of these cells, which can lead to the formation of tumors. This cancer often develops at the junction of the esophagus and stomach (gastroesophageal junction) and is associated with risk factors such as obesity, gastroesophageal reflux disease (GERD), smoking, and a diet low in fruits and vegetables. Symptoms may include difficulty swallowing, weight loss, chest pain, and persistent heartburn. Diagnosis typically involves imaging tests, endoscopy, and biopsy. Treatment options may include surgery, chemotherapy, radiation therapy, or targeted therapies, depending on the cancer’s stage and the patient’s overall health.

Get a Free sample for the Gastroesophageal Adenocarcinoma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/gastroesophageal-adenocarcinoma-market

Gastroesophageal Adenocarcinoma Epidemiology

Gastroesophageal Adenocarcinoma Epidemiology Segmentation:

The Gastroesophageal Adenocarcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Gastroesophageal Adenocarcinoma
Prevalent Cases of Gastroesophageal Adenocarcinoma by severity
Gender-specific Prevalence of Gastroesophageal Adenocarcinoma
Diagnosed Cases of Episodic and Chronic Gastroesophageal Adenocarcinoma

Download the report to understand which factors are driving Gastroesophageal Adenocarcinoma epidemiology trends @ Gastroesophageal Adenocarcinoma Epidemiology Forecast

Gastroesophageal Adenocarcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroesophageal Adenocarcinoma market or expected to get launched during the study period. The analysis covers Gastroesophageal Adenocarcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Gastroesophageal Adenocarcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroesophageal Adenocarcinoma Therapies and Key Companies

KEYTRUDA (pembrolizumab): Merck
LONSURF (trifluridine/ tipiracil): Taiho Pharmaceuticals
Sacituzumab Tirumotecan (MK-2870): Merck/Sichuan Kelun-Biotech
Evorpacept (ALX148): ALX Oncology
Paclitaxel: Canadian Cancer Trials Group
Trifluridine-Tipiracil: Merck Sharp & Dohme LLC
ASKB589: AskGene Pharma, Inc.
AK104: Akeso
OBP-301: Weill Medical College
tucatinib: Seagen Inc.
Docetaxel for injection (Albumin-bound): CSPC ZhongQi Pharmaceutical
Zanidatamab: Jazz Pharmaceuticals
Trastuzumab deruxtecan: Daiichi Sankyo
Capecitabine: RemeGen Co., Ltd.
Infigratinib: LianBio LLC
Atezolizumab: Hoffmann-La Roche
Bemarituzumab: Amgen
PT886: Phanes Therapeutics

Discover more about therapies set to grab major Gastroesophageal Adenocarcinoma market share @ Gastroesophageal Adenocarcinoma Treatment Landscape

Gastroesophageal Adenocarcinoma Market Drivers

Increasing Incidence Rates
Advancements in Treatment
Improved Diagnostic Techniques
Aging Population
Rising Awareness
Clinical Trials and Research

Gastroesophageal Adenocarcinoma Market Barriers

High Treatment Costs
Limited Early Detection
Side Effects of Treatment
Drug Resistance
Regulatory Hurdles
Geographical Disparities

Scope of the Gastroesophageal Adenocarcinoma Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Gastroesophageal Adenocarcinoma Companies: Merck, Taiho Pharmaceuticals, Sichuan Kelun-Biotech, ALX Oncology, Canadian Cancer Trials Group, AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., CSPC ZhongQi Pharmaceutical, Jazz Pharmaceuticals, Daiichi Sankyo, RemeGen Co., Ltd., LianBio LLC, Hoffmann-La Roche, Amgen, Phanes Therapeutics, and others
Key Gastroesophageal Adenocarcinoma Therapies: KEYTRUDA (pembrolizumab), LONSURF (trifluridine/ tipiracil), Sacituzumab Tirumotecan (MK-2870), Evorpacept (ALX148), Paclitaxel, Trifluridine-Tipiracil, ASKB589, AK104, OBP-301, tucatinib, Docetaxel for injection (Albumin-bound), Zanidatamab, Trastuzumab deruxtecan, Capecitabine, Infigratinib, Atezolizumab, Bemarituzumab, PT886, and others
Gastroesophageal Adenocarcinoma Therapeutic Assessment: Gastroesophageal Adenocarcinoma current marketed and Gastroesophageal Adenocarcinoma emerging therapies
Gastroesophageal Adenocarcinoma Market Dynamics: Gastroesophageal Adenocarcinoma market drivers and Gastroesophageal Adenocarcinoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Gastroesophageal Adenocarcinoma Unmet Needs, KOL’s views, Analyst’s views, Gastroesophageal Adenocarcinoma Market Access and Reimbursement

To know more about Gastroesophageal Adenocarcinoma companies working in the treatment market, visit @ Gastroesophageal Adenocarcinoma Clinical Trials and Therapeutic Assessment

Table of Contents

1. Gastroesophageal Adenocarcinoma Market Report Introduction

2. Executive Summary for Gastroesophageal Adenocarcinoma

3. SWOT analysis of Gastroesophageal Adenocarcinoma

4. Gastroesophageal Adenocarcinoma Patient Share (%) Overview at a Glance

5. Gastroesophageal Adenocarcinoma Market Overview at a Glance

6. Gastroesophageal Adenocarcinoma Disease Background and Overview

7. Gastroesophageal Adenocarcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroesophageal Adenocarcinoma

9. Gastroesophageal Adenocarcinoma Current Treatment and Medical Practices

10. Gastroesophageal Adenocarcinoma Unmet Needs

11. Gastroesophageal Adenocarcinoma Emerging Therapies

12. Gastroesophageal Adenocarcinoma Market Outlook

13. Country-Wise Gastroesophageal Adenocarcinoma Market Analysis (2020–2034)

14. Gastroesophageal Adenocarcinoma Market Access and Reimbursement of Therapies

15. Gastroesophageal Adenocarcinoma Market Drivers

16. Gastroesophageal Adenocarcinoma Market Barriers

17. Gastroesophageal Adenocarcinoma Appendix

18. Gastroesophageal Adenocarcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroesophageal Adenocarcinoma Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Merck, Taiho Pharma, Sichuan Kelun-Biotech, ALX Oncology, AskGene Pharma, Inc., Akeso

Iron Deficiency Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Shield Therapeutics, Zeria Pharma, Keros Therapeutics

The Key Iron Deficiency Anemia Companies in the market include – MegaPro Biomedical, Nemysis, Pharmacosmos A/S, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutics, Zeria Pharma, Keros Therapeutics, Inc., AMAG Pharma, JW Pharmaceutical, and others.

DelveInsight’s “Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Iron Deficiency Anemia, historical and forecasted epidemiology as well as the Iron Deficiency Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Iron Deficiency Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Iron Deficiency Anemia Market Forecast

Some of the key facts of the Iron Deficiency Anemia Market Report:

The Iron Deficiency Anemia market size was valued approximately ~USD 1,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
DelveInsight reported that Oral Ferrous Products (OFPs) generated nearly USD 80 million in revenue across the 7MM in 2023. Among these products, ferrous sulfate accounted for the highest revenue during that year.
In February 2024, The new SANOIN clinical study, backed by P&G Health (the healthcare division of P&G) and carried out by top healthcare professionals, revealed that iron supplementation with Sangobion (ferrous gluconate combined with multivitamins and minerals) effectively enhances Hemoglobin (Hb) levels and quality of life (QOL), providing symptom relief. The study results indicated a notable increase in Hb levels within 14 days, symptom relief within 30 days, and improved QOL for women suffering from Iron Deficiency Anemia.
In 2023, the United States had approximately 9,510,600 prevalent cases.
In 2023, it was noted that Iron Deficiency Anemia was more common in females than in males, making up about 65% of the cases.
In 2023, iron deficiency anemia cases in the United States were predominantly attributed to iron deficiency anemia (IDA) and chronic kidney disease, which together represented approximately 30% of the cases by pathology.
Companies such as Akebia Therapeutics (Keryx Biopharmaceuticals) in collaboration with Japan Tobacco (through its subsidiary Torii Pharmaceutical) and Shield Therapeutics in partnership with Norgine BV have entered the Iron Deficiency Anemia (IDA) market. This market was previously dominated by over-the-counter (OTC) and prescription oral iron products (OFPs) as well as intravenous (IV) iron treatments. These companies aim to provide safer, more effective, and more convenient oral medications for IDA patients.
Key Iron Deficiency Anemia Companies: MegaPro Biomedical, Nemysis, Pharmacosmos A/S, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutics, Zeria Pharma, Keros Therapeutics, Inc., AMAG Pharma, JW Pharmaceutical, and others
Key Iron Deficiency Anemia Therapies: MPB-1514 (IOP Injection), IDAX (IHAT-02), Ferric Derisomaltose, Low Dose IHAT, ferric citrate, iron isomaltoside 1000 (Monofer®), Ferric carboxymaltose, Ferric Maltol, Z-213, KER-047, Ferumoxytol, venoferrum(iron sucrose), Z-213, and others
The Iron Deficiency Anemia epidemiology based on gender analyzed that Iron Deficiency Anemia affects more females as compared to males
The Iron Deficiency Anemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Iron Deficiency Anemia pipeline products will significantly revolutionize the Iron Deficiency Anemia market dynamics.

Iron Deficiency Anemia Overview

Iron Deficiency Anemia (IDA) is a common type of anemia that occurs when the body lacks enough iron to produce hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. Hemoglobin is crucial for delivering oxygen from the lungs to other parts of the body and for returning carbon dioxide from the tissues back to the lungs.

Get a Free sample for the Iron Deficiency Anemia Market Report:

https://www.delveinsight.com/report-store/iron-deficiency-anemia-market

Iron Deficiency Anemia Epidemiology

Iron Deficiency Anemia Epidemiology Segmentation:

The Iron Deficiency Anemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Iron Deficiency Anemia
Prevalent Cases of Iron Deficiency Anemia by severity
Gender-specific Prevalence of Iron Deficiency Anemia
Diagnosed Cases of Episodic and Chronic Iron Deficiency Anemia

Download the report to understand which factors are driving Iron Deficiency Anemia epidemiology trends @ Iron Deficiency Anemia Epidemiology Forecast

Iron Deficiency Anemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Iron Deficiency Anemia market or expected to get launched during the study period. The analysis covers Iron Deficiency Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Iron Deficiency Anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Iron Deficiency Anemia Therapies and Key Companies

MPB-1514 (IOP Injection): MegaPro Biomedical
IDAX (IHAT-02): Nemysis
Ferric Derisomaltose: Pharmacosmos A/S
ferric citrate: Keryx Biopharmaceuticals
iron isomaltoside 1000 (Monofer®): Pharmacosmos A/S
Ferric carboxymaltose: Tigermed Consulting Co., Ltd
Ferric Maltol: Shield Therapeutics
Z-213: Zeria Pharma
KER-047: Keros Therapeutics, Inc.
Ferumoxytol: AMAG Pharma
venoferrum(iron sucrose): JW Pharmaceutical
Z-213: Zeria Pharma

Discover more about therapies set to grab major Iron Deficiency Anemia market share @ Iron Deficiency Anemia Treatment Market

Iron Deficiency Anemia Market Drivers

Increasing changes in lifestyle
Increasing cases of anemia
Growth in geriatric population

Iron Deficiency Anemia Market Barriers

Extensive usage of over-the-counter (OTC) medications
Availability of generics
Lack of robust pipeline

Scope of the Iron Deficiency Anemia Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Iron Deficiency Anemia Companies: MegaPro Biomedical, Nemysis, Pharmacosmos A/S, Keryx Biopharmaceuticals, Pharmacosmos A/S, Tigermed Consulting Co., Ltd, Shield Therapeutics, Zeria Pharma, Keros Therapeutics, Inc., AMAG Pharma, JW Pharmaceutical, and others
Key Iron Deficiency Anemia Therapies: MPB-1514 (IOP Injection), IDAX (IHAT-02), Ferric Derisomaltose, Low Dose IHAT, ferric citrate, iron isomaltoside 1000 (Monofer®), Ferric carboxymaltose, Ferric Maltol, Z-213, KER-047, Ferumoxytol, venoferrum(iron sucrose), Z-213, and others
Iron Deficiency Anemia Therapeutic Assessment: Iron Deficiency Anemia current marketed and Iron Deficiency Anemia emerging therapies
Iron Deficiency Anemia Market Dynamics: Iron Deficiency Anemia market drivers and Iron Deficiency Anemia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Iron Deficiency Anemia Unmet Needs, KOL’s views, Analyst’s views, Iron Deficiency Anemia Market Access and Reimbursement

To know more about Iron Deficiency Anemia companies working in the treatment market, visit @ Iron Deficiency Anemia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Iron Deficiency Anemia Market Report Introduction

2. Executive Summary for Iron Deficiency Anemia

3. SWOT analysis of Iron Deficiency Anemia

4. Iron Deficiency Anemia Patient Share (%) Overview at a Glance

5. Iron Deficiency Anemia Market Overview at a Glance

6. Iron Deficiency Anemia Disease Background and Overview

7. Iron Deficiency Anemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Iron Deficiency Anemia

9. Iron Deficiency Anemia Current Treatment and Medical Practices

10. Iron Deficiency Anemia Unmet Needs

11. Iron Deficiency Anemia Emerging Therapies

12. Iron Deficiency Anemia Market Outlook

13. Country-Wise Iron Deficiency Anemia Market Analysis (2020–2034)

14. Iron Deficiency Anemia Market Access and Reimbursement of Therapies

15. Iron Deficiency Anemia Market Drivers

16. Iron Deficiency Anemia Market Barriers

17. Iron Deficiency Anemia Appendix

18. Iron Deficiency Anemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Iron Deficiency Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Shield Therapeutics, Zeria Pharma, Keros Therapeutics

Knee Osteoarthritis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Paradigm Biopharma, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc

The Key Knee Osteoarthritis Companies in the market include – Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutic, Noven Pharmaceuticals, Kolon TissueGene, Paradigm Biopharmaceuticals, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech Australia, Grünenthal GmbH, Akan Biosciences, LLC, GlaxoSmithKline, and others.

DelveInsight’s “Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Knee Osteoarthritis, historical and forecasted epidemiology as well as the Knee Osteoarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Knee Osteoarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Knee Osteoarthritis Market Forecast

Some of the key facts of the Knee Osteoarthritis Market Report:

The Knee Osteoarthritis market size was valued ~USD 14, 400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In September 2024, Cytonics has announced the completion of patient enrollment in a Phase I clinical trial for CYT-108, which is being investigated as a potential disease-modifying therapy for knee osteoarthritis (OA). CYT-108 is a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor.
Among the 7MM, the US holds the largest market size for knee osteoarthritis (OA). This growth is driven by the emergence of new therapies, with the market size for knee OA estimated to be around USD 8,900 million in 2023.
In May 2024, Organogenesis reported encouraging topline results from a Phase III randomized controlled trial assessing the safety and effectiveness of ReNu in managing symptoms of knee osteoarthritis.
In 2023, the US recorded the highest number of prevalent cases, totaling approximately 18,499,200, followed by Japan.
In the US, the age group of 70 years and older represented the highest number of cases in 2023, while the lowest number of cases was observed in the 18–39 age group.
A study by Yokota et al. (2023) indicates that knee osteoarthritis is highly prevalent in Japan, affecting an estimated 25.3 million individuals over the age of 40, with around 8 million experiencing symptomatic cases.
In 2023, there were approximately 97 million diagnosed cases of knee osteoarthritis in the 7MM. This number is expected to rise during the forecast period from 2024 to 2034.
In 2023, within the EU4 and the UK, the highest proportion of age-specific knee osteoarthritis cases were observed in individuals aged 70 and above, followed by those in the 60-69 and 50-59 age groups.
Key Knee Osteoarthritis Companies: Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutic, Noven Pharmaceuticals, Kolon TissueGene, Paradigm Biopharmaceuticals, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech Australia, Grünenthal GmbH, Akan Biosciences, LLC, GlaxoSmithKline, and others
Key Knee Osteoarthritis Therapies: TLC599, CNTX-4975, Lorecivivint (SM04690), HP-5000, Invossa (TG-C), ZILOSUL (pentosan polysulfate sodium), ReNu (Amniotic Suspension Allograft), JTA-004, Resiniferatoxin, ICM-203, RTX-GRT7039, StroMel, GSK3858279, and others
The Knee Osteoarthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Knee Osteoarthritis pipeline products will significantly revolutionize the Knee Osteoarthritis market dynamics.

Knee Osteoarthritis Overview

Knee Osteoarthritis (OA) is a progressive, degenerative joint disease that affects the knee, causing significant pain, stiffness, and functional impairment. It involves the breakdown of the cartilage that cushions the ends of the bones in the knee joint, leading to symptoms that can severely impact daily activities and quality of life.

Get a Free sample for the Knee Osteoarthritis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/knee-osteoarthritis-market

Knee Osteoarthritis Epidemiology

Knee Osteoarthritis Epidemiology Segmentation:

The Knee Osteoarthritis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Knee Osteoarthritis
Prevalent Cases of Knee Osteoarthritis by severity
Gender-specific Prevalence of Knee Osteoarthritis
Diagnosed Cases of Episodic and Chronic Knee Osteoarthritis

Download the report to understand which factors are driving Knee Osteoarthritis epidemiology trends @ Knee Osteoarthritis Epidemiology Forecast

Knee Osteoarthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Knee Osteoarthritis market or expected to get launched during the study period. The analysis covers Knee Osteoarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Knee Osteoarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Knee Osteoarthritis Therapies and Key Companies

TLC599: Taiwan Liposome Company
CNTX-4975: Centrexion Therapeutics
Lorecivivint (SM04690): Biosplice Therapeutic
HP-5000: Noven Pharmaceuticals
Invossa (TG-C): Kolon TissueGene
ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals
ReNu (Amniotic Suspension Allograft): Organogenesis
JTA-004: BioSenic (Bone Therapeutics)
Resiniferatoxin: Sorrento Therapeutics, Inc.
ICM-203: ICM Biotech Australia
RTX-GRT7039: Grünenthal GmbH
StroMel: Akan Biosciences, LLC
GSK3858279: GlaxoSmithKline

Discover more about therapies set to grab major Knee Osteoarthritis market share @ Knee Osteoarthritis Treatment Landscape

Knee Osteoarthritis Market Strengths

New approaches to osteoarthritis therapy currently being investigated include attempts to identify disease-modifying osteoarthritis drugs, tissue engineering for reconstituting intact cartilage and joint tissues, and biomechanically active methods for reducing aberrant loading in osteoarthritis-involved joints.
Single injection joint function enhancing hyaluronic acid formulation’s sales are steadily rising, and companies are looking to expand into new markets to increase their single injection product profit.

Knee Osteoarthritis Market Opportunities

Disease-modifying osteoarthritis drugs (DMOADs) could offer new therapeutic targets to restore the quality and function of tissues affected by osteoarthritis.
People eagerly await non-opioid options, and key players can target this lucrative market segment while others are developing therapies for the same.

Scope of the Knee Osteoarthritis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Knee Osteoarthritis Companies: Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutic, Noven Pharmaceuticals, Kolon TissueGene, Paradigm Biopharmaceuticals, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech Australia, Grünenthal GmbH, Akan Biosciences, LLC, GlaxoSmithKline, and others
Key Knee Osteoarthritis Therapies: TLC599, CNTX-4975, Lorecivivint (SM04690), HP-5000, Invossa (TG-C), ZILOSUL (pentosan polysulfate sodium), ReNu (Amniotic Suspension Allograft), JTA-004, Resiniferatoxin, ICM-203, RTX-GRT7039, StroMel, GSK3858279, and others
Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies
Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Knee Osteoarthritis Unmet Needs, KOL’s views, Analyst’s views, Knee Osteoarthritis Market Access and Reimbursement

To know more about Knee Osteoarthritis companies working in the treatment market, visit @ Knee Osteoarthritis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Knee Osteoarthritis Market Report Introduction

2. Executive Summary for Knee Osteoarthritis

3. SWOT analysis of Knee Osteoarthritis

4. Knee Osteoarthritis Patient Share (%) Overview at a Glance

5. Knee Osteoarthritis Market Overview at a Glance

6. Knee Osteoarthritis Disease Background and Overview

7. Knee Osteoarthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Knee Osteoarthritis

9. Knee Osteoarthritis Current Treatment and Medical Practices

10. Knee Osteoarthritis Unmet Needs

11. Knee Osteoarthritis Emerging Therapies

12. Knee Osteoarthritis Market Outlook

13. Country-Wise Knee Osteoarthritis Market Analysis (2020–2034)

14. Knee Osteoarthritis Market Access and Reimbursement of Therapies

15. Knee Osteoarthritis Market Drivers

16. Knee Osteoarthritis Market Barriers

17. Knee Osteoarthritis Appendix

18. Knee Osteoarthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Knee Osteoarthritis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Paradigm Biopharma, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc

FIREDISC Cookers: A History of Innovation and A Triumphant Return to ACE Hardware Distribution Centers, Offering Portable Outdoor Cooking Solutions Nationwide

CEO Griff Jaggard stated, “We are thrilled to be back with ACE Hardware. Their commitment to quality and customer service aligns perfectly with FIREDISC’s mission.”

FIREDISC Cookers, the original outdoor propane cooking disc, is excited to announce its return to ACE Hardware Distribution Centers nationwide. This renewed partnership brings FIREDISC products, including their portable propane cookers, outdoor griddles, and propane BBQ grills, back to ACE Hardware locations across the country. CEO Griff Jaggard stated, “We are thrilled to be back with ACE Hardware. Their commitment to quality and customer service aligns perfectly with FIREDISC’s mission.”

FIREDISC Cookers, the original outdoor propane cooking disc, is excited to announce its return to ACE Hardware Distribution Centers nationwide. This renewed partnership brings FIREDISC products, including their portable propane cookers, outdoor griddles, and propane BBQ grills, back to ACE Hardware locations across the country. CEO Griff Jaggard stated, “We are thrilled to be back with ACE Hardware. Their commitment to quality and customer service aligns perfectly with FIREDISC’s mission.”

FIREDISC’s propane disc cookers, designed for outdoor enthusiasts, offer versatility for all types of cooking—from backyard barbecues to tailgating and camping. These high-quality, durable outdoor grills now available at ACE Hardware are a top choice for those who value convenience and performance. ACE Hardware’s extensive retail distribution allows FIREDISC Cookers to reach even more customers at their trusted local ACE Hardware locations.

This partnership will see ACE Hardware carrying a wide range of FIREDISC products, including portable propane cookers, outdoor griddles, and accessories such as the FIREDISC Spatula Ultimate Cooking Weapon, FIREDISC Wind Helmet, FIREDISC Disc Sac and FIREDISC Universal Cooker Cover. These products available at ACE Hardware are built to last and have earned a reputation for outstanding performance among outdoor chefs.

The return of FIREDISC Cookers to ACE Hardware Distribution Centers marks a key milestone in the brand’s growth, solidifying its position as a leader in the outdoor cooking market. ACE Hardware locations will now feature these top-tier products, providing customers with easy access to the best portable propane BBQ grills and cookers. Whether you’re grilling at home or on the go, FIREDISC and ACE Hardware are committed to delivering superior outdoor cooking experiences.

As FIREDISC Cookers continues to expand its retail distribution, the partnership with ACE Hardware underscores the brand’s success and dedication to providing premium outdoor cooking solutions. Visit your nearest ACE Hardware location to discover the full line of FIREDISC propane cookers and accessories and experience the portability of cooking with a FIREDISC.

For more information about FIREDISC Cookers and to find your local ACE Hardware retailer, visit the FIREDISC website or follow them on social media.

About FIREDISC Cookers:

Headquartered in Katy, Texas, FIREDISC® is a leading national brand specializing in the design, manufacturing, distribution, and retail of innovative outdoor cooking products. From portable propane cookers and rugged accessories to heavy-duty utensils and apparel, FIREDISC® makes outdoor cooking accessible, effortless, and enjoyable for everyone — because time with family and friends is more precious than ever. Engineered to be both versatile and portable, FIREDISC® Cookers can handle any meal, anywhere you go. Whether it’s a quick dinner in the backyard or a weekend gathering on the move, FIREDISC® turns good food into great memories. Committed to matching the portability of their products with exceptional customer service, this family-owned, Texas-based company has cultivated a devoted nationwide following since its launch in 2017. From renowned outdoor enthusiasts to those who simply appreciate top-tier portability, durability, and versatility, FIREDISC® has become a trusted name in outdoor cooking. As they look to the future, FIREDISC® remains dedicated to creating superior products for those who love the outdoor lifestyle. Fire it Up and Gather ‘Round.

About ACE Hardware:

ACE Hardware is the largest retailer-owned hardware cooperative in the world, known for its exceptional customer service and vast selection of high-quality home and outdoor products.

For more info, contact:

Griff Jaggard
Firedisc
Email: griff@firedisccookers.com

Media Contact
Company Name: FIREDISC, INC.
Contact Person: Griff Jaggard
Email: Send Email
Phone: 2812062678
Address:25145 Star Ln, Suite 1103
City: Katy
State: Texas 77494
Country: United States
Website: https://www.firedisccookers.com/

Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd

The Key Pancreatic Cancer Companies in the market include – AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others.

The Pancreatic Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Pancreatic Cancer market dynamics.

DelveInsight’s “Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Pancreatic Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pancreatic Cancer Market Forecast

Some of the key facts of the Pancreatic Cancer Market Report:

The Pancreatic Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In January 2023, Strong interim findings from the current OPTIMIZE-1 Phase 2 study of the company’s flagship asset, mitazalimab, in first-line metastatic pancreatic cancer, were released by Alligator Bioscience. In an open-label, multi-center research, patients with metastatic pancreatic ductal adenocarcinoma who had not previously received treatment are being evaluated for the safety and efficacy of mitazalimab (CD40 mAb) in conjunction with the chemotherapeutic drug mFOLFIRINOX.
According to DelveInsight’s estimates, the total incident cases of pancreatic cancer in the United States accounted for approximately 35% in 2023.
The 2023 analysis indicates that the highest stage-specific incident cases of pancreatic cancer in the US were for distant stages, comprising nearly 50% of cases, followed by regional and localized stages.
The mutation types associated with pancreatic cancer include KRAS2, TP53, SMAD4/DPC4, BRCA1/2, MSI-H/dMMR, and NTRK. In the United States, KRAS2 and TP53 were responsible for the largest number of incident cases of pancreatic cancer in 2023.
Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others
Key Pancreatic Cancer Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others
The Pancreatic Cancer epidemiology based on gender analyzed that males are more commonly affected in case of Pancreatic Cancer than females

Request a sample for the Pancreatic Cancer Market Report:

https://www.delveinsight.com/report-store/pancreatic-cancer-market

Pancreatic Cancer Overview

Pancreatic adenocarcinoma is one of the most aggressive forms of cancer and is projected to arise as the second leading cause of cancer-related deaths in Europe and the United States in the near future. In the US, pancreatic cancer is the 9th or 10th most commonly diagnosed cancer (depending on gender). A clinical/radiographic stage classification for pancreatic cancer suggests three stage classification(potentially resectable, locally advanced, and advanced) of pancreatic cancer involvement based on radiological findings.

Localized pancreatic cancer is the one that remains confined to its location of origin and does not spreads out. Surgery remains the only option for these kinds of cancer cells. • Locally advanced Pancreatic Cancer is a non-metastasized pancreatic cancer, in which upfront resection is considered not beneficial due to extensive vascular involvement and the consequent high chance of a nonradical resection. These patients have significant symptom burdens referable to their primary malignancy, including pain (usually in the abdomen or back), pancreatic insufficiency, biliary obstruction, and early satiety/gastric outlet obstruction, weight loss, jaundice (yellowing of the skin, eyes or both)with or without itching, loss of appetite, nausea, change in stool, pancreatitis, recent-onset diabetes.

Pancreatic Cancer Epidemiology Segmentation:

The Pancreatic Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Pancreatic Cancer
Prevalent Cases of Pancreatic Cancer by severity
Gender-specific Prevalence of Pancreatic Cancer
Diagnosed Cases of Episodic and Chronic Pancreatic Cancer

Download the report to understand which factors are driving Pancreatic Cancer epidemiology trends @ Pancreatic Cancer Epidemiological Insights

Pancreatic Cancer Market

The dynamics of the Pancreatic Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Niraparib, Dostarlimab, and others during the forecasted period 2020-2034.

Pancreatic Cancer Therapies and Key Companies

LYNPARZA (olaparib): AstraZeneca
KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
Elraglusib (9 ING 41): Actuate Therapeutics
DF 7001: Dragonfly Therapeutics CMG 901 Keymed B
TNG260: Tango Therapeutics
ATA 3271: Atara Biotherapeutics
CMG 901: Keymed Biosciences Co.Ltd
CT-0508: Carisma Therapeutics Inc
CUE-102: Cue Biopharma
BOLD-100: Bold Therapeutics
CM24: Purple Biotech Ltd
ENB-003: ENB Therapeutics
GRT-C903: Gritstone bio
AZD0171: AstraZeneca
CAN-2409: Candel Therapeutics
Mitazalimab: Alligator Bioscience
Pamrevlumab: FibroGen
NIS793: Novartis AG
Masitinib: AB Science
Glufosfamide: Eleison Pharmaceuticals

To know more about Pancreatic Cancer treatment, visit @ Pancreatic Cancer Medications

Pancreatic Cancer Market Drivers

Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of Pancreatic Cancer
Strong pipeline activity

Pancreatic Cancer Market Barriers

Rising incidence of cancer will provide a larger window of opportunity for new treatments
Reoccurrence is very common in cancers even after proper treatment; this opens up a new window for pipeline activity

Scope of the Pancreatic Cancer Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics CMG 901 Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others
Key Pancreatic Cancer Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others
Therapeutic Assessment: Pancreatic Cancer current marketed and Pancreatic Cancer emerging therapies
Market Dynamics: Pancreatic Cancer market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Pancreatic Cancer Market Access and Reimbursement

Discover more about therapies set to grab major Pancreatic Cancer market share @ Pancreatic Cancer Treatment Landscape

Table of Contents

1. Pancreatic Cancer Market Report Introduction

2. Executive Summary for Pancreatic Cancer

3. SWOT analysis of Pancreatic Cancer

4. Pancreatic Cancer Patient Share (%) Overview at a Glance

5. Pancreatic Cancer Market Overview at a Glance

6. Pancreatic Cancer Disease Background and Overview

7. Pancreatic Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Pancreatic Cancer

9. Pancreatic Cancer Current Treatment and Medical Practices

10. Pancreatic Cancer Unmet Needs

11. Pancreatic Cancer Emerging Therapies

12. Pancreatic Cancer Market Outlook

13. Country-Wise Pancreatic Cancer Market Analysis (2020–2034)

14. Pancreatic Cancer Market Access and Reimbursement of Therapies

15. Pancreatic Cancer Market drivers

16. Pancreatic Cancer Market barriers

17. Pancreatic Cancer Appendix

18. Pancreatic Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd

Actelis Networks Expands Military Sector Presence with $200,000 Order for National Guard Base Upgrade

Actelis Networks (NASDAQ: ASNS) a leader in hybrid-fiber networking solutions designed for IoT applications and cyber-hardened environments, has announced a $200,000 order from the U.S. Department of Military Affairs. This order will enable a U.S. Army National Guard base to modernize its network infrastructure using Actelis’ cutting-edge hybrid-fiber technology. This development is a continuation of Actelis’ growing influence in the federal government and military sectors, highlighting its reputation for delivering rapid, secure, and cost-effective networking solutions.

Strengthening Military Ties

This order builds on a series of recent wins for Actelis in the government sector, which includes a $150,000 order in July for a tier-1 military contractor for its advanced GigaLine 800 solution. Actelis’ technology is gaining traction in military applications due to its ability to significantly increase bandwidth without requiring extensive and costly infrastructure upgrades.

“We are honored to support the U.S. military’s critical operations by providing a fast and reliable solution that meets their stringent requirements,” said Tuvia Barlev, Chairman and CEO of Actelis. “Our hybrid-fiber technology allows for rapid deployment, high bandwidth, and robust security, which are essential for military installations.”

Expanding Role in Transportation

Actelis’ growth is not limited to the military sector. The company recently secured a series of contracts in the transportation industry, underlining its versatility and the broad applicability of its networking solutions. Earlier this month, Actelis announced a new order for a major U.S. aerial transportation agency, following a $2.3 million deal with Washington D.C.’s Department of Transportation in May, a $300,000 agreement for an Italian national transportation infrastructure project in June, and a $260,000 order for a Mid-Atlantic U.S. county traffic system in July.

Actelis’ ability to deliver rapid upgrades to existing networks makes it a preferred choice for clients in both the transportation and defense sectors. By leveraging the existing physical cabling infrastructure, Actelis can provide immediate bandwidth improvements, enabling the rapid deployment of IoT devices and broadband services with minimal disruption.

“Our customers deliver critical services to their communities, and we’re proud to play a key role by providing the essential connectivity and data transmission solutions they need, all secured by our cyber-hardened platform to protect their networks,” Barlev noted.

Pioneering Cybersecurity Initiatives

In addition to its physical networking solutions, Actelis (NASDAQ:ASNS) is also innovating in the cybersecurity space. Last month, the company announced the upcoming debut of its AI-powered Cybersecurity SaaS solution for IoT networks. Developed in partnership with an advanced cybersecurity provider, this software is part of Actelis’ Cyber Aware Networking initiative and is designed to protect physical assets such as cameras, sensors, and other edge devices.

This novel cybersecurity solution integrates directly into Actelis’ networking devices, enabling real-time monitoring and threat detection across IoT networks. It provides enterprise-grade AI asset intelligence and threat management capabilities, enhancing the security and operational continuity of critical infrastructure networks, including those operated by local and federal government agencies, utility providers, and transportation systems.

“With tens of thousands of Actelis devices deployed worldwide in critical IoT networks, data security is paramount,” Barlev explained. “By adding an additional layer of protection to our customers’ operational environments, we’re offering a powerful platform that not only detects and reports cyber-attacks and operational faults but also enables immediate, actionable responses by the communication network before these issues escalate.”

Strategic Partnerships and Future Prospects

Actelis’ recent partnerships and product developments indicate a strategic focus on expanding its market presence in the IoT sector. The company’s Cyber Aware Networking initiative, which integrates AI-based cyber monitoring and protection for edge devices, is a clear signal of its commitment to addressing the evolving cybersecurity needs of its clients.

The $200,000 order for the National Guard base is just the latest in a series of contracts that highlight Actelis’ growing role in providing secure, scalable, and cost-effective networking solutions. Its listing on the Department of Defense’s Approved Products List (APL) and certifications such as JITC and NIST for FIPS compliance underscore the company’s ability to meet the highest cybersecurity standards, providing government agencies with confidence in their networking infrastructure.

Outlook

As Actelis Networks continues to expand its footprint in both the military and transportation sectors, its hybrid-fiber technology and advanced cybersecurity offerings may position it as a key player in the secure networking space. With a strong track record of rapid, secure deployments and a growing list of high-profile clients, Actelis could be well-positioned to capitalize on future opportunities in the defense and government markets.

The company’s recent orders and product launches seem to demonstrate its ability to innovate and adapt to the needs of complex and demanding environments, making Actelis a company to watch in the evolving landscape of secure networking technology.

This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, reccomendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. https://justpaste.it/ecto7/pdf. Global Markets News Network is compensated to publish and syndicate commentary and exploration into innovative companies and it is subject to conflicts of interest detailed in the documentation.

Media Contact
Company Name: Global Markets News Network
Contact Person: Editorial Desk
Email: Send Email
Country: Canada
Website: https://www.futuremarketsresearch.com/global-markets-news

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Actelis Networks Expands Military Sector Presence with $200,000 Order for National Guard Base Upgrade

Health Insurance Broker in Greenville, SC, Launches Educational TV Campaign on Major Networks

True Heart Insurance, led by prominent insurance broker in Greenville, SC, Joshua Dixson, is set to launch an extensive educational TV campaign this fall. This campaign will feature 100 commercials aired on major networks such as CNN, MSNBC, Lifetime, and HGTV, aimed at educating the Greenville community about the importance of strong and affordable health insurance. This initiative reflects True Heart Insurance’s commitment to making comprehensive insurance solutions more accessible and understandable to a broader audience.

The TV commercials are part of a larger outreach strategy that includes a feature in the first-ever Greenville edition of Community Insider Magazine. The magazine, available in over 80 locations throughout the area, will serve as an additional platform for True Heart Insurance to connect with local residents. By leveraging both print and television media, the agency aims to reach a diverse audience and provide them with the knowledge needed to make informed decisions about their health insurance options.

“We at the True Heart Insurance agency are thrilled to extend our outreach in the Greenville area through this TV campaign,” said Joshua Dixson, an independent insurance broker in Greenville, SC. “Our commercials will not only highlight the benefits of having affordable health insurance but also guide individuals and families on how to choose the best coverage for their needs. Our goal is to ensure that everyone has access to the information they need to secure their health and financial future.”

In addition to the TV campaign, the agency’s feature in Community Insider Magazine will include a full-page ad, reinforcing their presence as a leading insurance company in Greenville, SC. The magazine is expected to be released in late September or early October, with the TV commercials following approximately six weeks later, creating a sustained awareness drive.

True Heart Insurance has built a reputation for helping clients secure health insurance in Greenville, SC, and beyond. Their dedication to client education and support sets them apart as a trusted resource in the community. For more information about their services and how they can help you find the best insurance solutions, visit their website at https://www.trueheartinsurance.com/.

Media Contact
Company Name: True Heart Insurance | Insurance agency in Greenville, SC
Contact Person: Joshua Dixson
Email: Send Email
Phone: +1 864-365-2724
Address:24 Blanche Rd
City: Greenville
State: South Carolina 29617
Country: United States
Website: https://www.trueheartinsurance.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Health Insurance Broker in Greenville, SC, Launches Educational TV Campaign on Major Networks